Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Nicotine replacement treatment (NRT) can be efficacious for smoking cessation, but used by only a minority of smokers in China. Pharmacogenetic matching may improve treatment outcomes for NRT in subgroups of smokers. The investigators evaluated the efficacy and safety of sublingual nicotine tablets (SNT) for smoking cessation and the association of catechol-O-methyltransferase (COMT) genotype with efficacy in this smoking cessation trial among Chinese smokers.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute on Drug Dependence, China
• Collaborator: Bronx VA Medical Center
• Treatments: Nicotine

Criteria

Inclusion Criteria:

• Subjects motivated to stop smoking and Han Chinese

• aged 20-70 years who lived in the Haidian District of Beijing

• smoke ≥10 cigarettes/day

• have smoked for ≥3 years

• carbon monoxide (CO) level ≥10 p.p.m. in exhaled air

Exclusion Criteria:

• a history of "Diagnostic and Statistical Manual of Mental Disorders-fourth Edition" (DSM-IV) psychiatric disorder

• alcohol abuse and other drug abuse

• with pathological changes in the floor of their mouth

• cardiovascular disease

• taking psychotropic medications

• using other forms of tobacco or any other NRT products during the last 6 months

• pregnant or breast-feeding